1. Academic Validation
  2. O‑GlcNAcylation mediates endometrial cancer progression by regulating the Hippo‑YAP pathway

O‑GlcNAcylation mediates endometrial cancer progression by regulating the Hippo‑YAP pathway

  • Int J Oncol. 2023 Aug;63(2):90. doi: 10.3892/ijo.2023.5538.
Lianghao Zhai 1 Xiaoshan Yang 2 Jian Dong 1 Luomeng Qian 3 Yunge Gao 1 Yanhong Lv 1 Ligang Chen 1 Biliang Chen 1 Fuxing Zhou 1
Affiliations

Affiliations

  • 1 Department of Gynecology and Obstetrics, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi 710032, P.R. China.
  • 2 Stomatology Hospital, Southern Medical University, Guangzhou, Guangdong 510280, P.R. China.
  • 3 Department of Medicine, Nankai University, Tianjin 300071, P.R. China.
Abstract

The incidence of endometrial Cancer (EC) is rapidly increasing worldwide. The majority of endometrial cancers are diagnosed at an early stage and are associated with a good prognosis; however, patients with advanced‑stage EC have a poor prognosis and present with invasive metastasis. The mechanisms responsible for the invasion and metastasis of endometrial Cancer remain unknown. Here, the present study aimed to examine the effects of O‑GlcNAcylation on the malignancy of EC and its association with Yes‑associated protein (YAP). It was found that the expression of O‑GlcNAc transferase (OGT) and O‑GlcNAcylation were increased in EC tissues; the decrease in O‑GlcNAcylation levels was found to lead to the decreased proliferation, migration and invasion of EC cells. Mass spectrometric analysis revealed that OGT knockdown reduced the O‑GlcNAcylation of YAP. Furthermore, it was found that the reduction in the O‑GlcNAcylation of YAP promoted its phosphorylation, which in turn inhibited the access of YAP to the nucleus and downstream target gene activation, demonstrating that the level of O‑GlcNAcylation affects the development of EC. On the whole, the findings of the present study indicate that YAP is a key molecule linking the O‑GlcNAcylation and Hippo pathways, which together regulate the progression of EC.

Keywords

O‑GlcNAc; O‑GlcNAc transferase; Yes‑associated protein; endometrial cancer.

Figures
Products
Inhibitors & Agonists
Other Products